Amedisys Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Amedisys wird ein Gewinn- und Umsatzwachstum von 38.9% bzw. 6.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 38.9% pro Jahr wachsen soll.

Wichtige Informationen

38.9%

Wachstumsrate der Gewinne

38.9%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	20.9%
Wachstumsrate der Einnahmen	6.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	20 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Sep 04

Amedisys: ROIC, Tangible Book Value Each Softening

Aug 24

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Aug 04

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

Jul 27

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Jul 20

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jun 04

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

May 05

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Apr 20

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Apr 06

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Feb 20

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Dec 03

These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Nov 18

Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Aug 18

Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Jul 23

Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity

Jul 18

Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

Jun 28

It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Jun 02

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

May 24

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:AMED - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2,701	178	N/A	N/A	1
12/31/2025	2,497	157	182	189	11
12/31/2024	2,346	99	179	187	10
9/30/2024	2,321	83	204	212	N/A
6/30/2024	2,290	92	88	96	N/A
3/31/2024	2,251	-21	91	105	N/A
12/31/2023	2,236	-10	124	137	N/A
9/30/2023	2,228	3	105	118	N/A
6/30/2023	2,229	2	101	114	N/A
3/31/2023	2,234	112	103	111	N/A
12/31/2022	2,223	119	126	133	N/A
9/30/2022	2,220	121	91	98	N/A
6/30/2022	2,216	140	166	173	N/A
3/31/2022	2,222	191	177	184	N/A
12/31/2021	2,214	209	182	189	N/A
9/30/2021	2,206	220	242	250	N/A
6/30/2021	2,196	247	264	271	N/A
3/31/2021	2,117	202	331	337	N/A
12/31/2020	2,072	184	284	289	N/A
9/30/2020	2,021	166	294	298	N/A
6/30/2020	1,972	128	256	263	N/A
3/31/2020	1,980	127	180	188	N/A
12/31/2019	1,956	127	194	202	N/A
9/30/2019	1,889	127	184	191	N/A
6/30/2019	1,812	124	204	212	N/A
3/31/2019	1,731	123	197	203	N/A
12/31/2018	1,663	119	217	223	N/A
9/30/2018	1,626	88	184	192	N/A
6/30/2018	1,583	71	N/A	133	N/A
3/31/2018	1,546	42	N/A	119	N/A
12/31/2017	1,511	30	N/A	106	N/A
9/30/2017	1,474	43	N/A	102	N/A
6/30/2017	1,456	40	N/A	99	N/A
3/31/2017	1,438	46	N/A	77	N/A
12/31/2016	1,419	37	N/A	62	N/A
9/30/2016	1,391	41	N/A	54	N/A
6/30/2016	1,358	38	N/A	78	N/A
3/31/2016	1,313	38	N/A	106	N/A
12/31/2015	1,266	-3	N/A	108	N/A
9/30/2015	1,230	-7	N/A	92	N/A
6/30/2015	1,204	-7	N/A	87	N/A
3/31/2015	1,193	-10	N/A	-45	N/A
12/31/2014	1,188	13	N/A	-66	N/A
9/30/2014	1,191	-4	N/A	-62	N/A
6/30/2014	1,192	-103	N/A	-59	N/A
3/31/2014	1,203	-109	N/A	64	N/A
12/31/2013	1,233	-93	N/A	102	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AMEDDas prognostizierte Gewinnwachstum (38.9% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: AMEDDie Erträge des Unternehmens (38.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.4% pro Jahr).

Hohe Wachstumserträge: AMEDEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: AMEDDie Einnahmen des Unternehmens (6.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: AMEDDie Einnahmen des Unternehmens (6.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von AMED in 3 Jahren voraussichtlich hoch sein wird

Amedisys Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 22%

Consensus EPS estimates fall by 54%

Price target decreased by 8.5% to US$98.85

Consensus EPS estimates fall by 16%

Price target decreased to US$126

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Recent updates

Consensus EPS estimates fall by 22%

Third quarter 2024 earnings: EPS misses analyst expectations

Final Push For Amedisys As UnitedHealth Awaits Regulatory Clearance

Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings: EPS misses analyst expectations

Full year 2023 earnings: EPS misses analyst expectations

Insufficient new directors

President notifies of intention to sell stock

Consensus EPS estimates fall by 54%

Third quarter 2023 earnings: EPS misses analyst expectations

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Investor sentiment improves as stock rises 19%

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Price target decreased by 8.5% to US$98.85

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS exceeds analyst expectations

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

Chairman & CEO exercised options and sold US$221k worth of stock

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

High number of new directors

Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Consensus EPS estimates fall by 16%

Price target decreased to US$126

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Amedisys: ROIC, Tangible Book Value Each Softening

Consensus EPS estimates fall by 11%

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Price target decreased to US$145

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Price target decreased to US$160

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Price target decreased to US$174

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Investor sentiment improved over the past week

Price target decreased to US$184

Chairman & CEO exercised options and sold US$2.8m worth of stock

Full year 2021 earnings: EPS misses analyst expectations

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

High number of new directors